RxDoctor Payments Data

Leslie Baum, APRN

Family · Jackson, TNNPI 1669101309

Payments from drug & device makers

$1,292in general payments, 2019–2025

Across 39 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$209
  • AstraZeneca$140
  • Scpharmaceuticals Inc.$140
  • Travere Therapeutics, Inc.$123
  • Novartis$105
  • Amgen$104
  • plus $469 from 9 others

What the payments were for

  • Food & beverage$1,25297%
  • Education$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,292 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$20,856
Medicare patients
169
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol70$49,099
JardianceEmpagliflozin17$12,466
Calcitriol66$819
Famotidine73$605
Valsartan34$576
Losartan Potassium96$571
Hydralazine Hcl21$373
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$344
Midodrine Hcl11$331
Carvedilol67$294
Nifedipine ErNifedipine34$291
Lisinopril49$246
Amlodipine Besylate53$218
Furosemide70$199
Vitamin D2Ergocalciferol (Vitamin D2)48$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$140$49,09970 claims
Boehringer IngelheimJardiance$56$12,46617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →